| 1 |
35287683 | Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer. | 2022 Mar 14 |
1 |
| 2 |
33621951 | MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts. | 2021 Feb 17 |
2 |
| 3 |
33724860 | Thermal treatment decreases resistance to osimertinib in non-small cell lung cancer through the EGFR/PI3K/AKT pathway. | 2021 May |
1 |
| 4 |
33812963 | Polyphyllin I reverses the resistance of osimertinib in non-small cell lung cancer cell through regulation of PI3K/Akt signaling. | 2021 May 15 |
1 |
| 5 |
34077739 | Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib. | 2021 Aug |
1 |
| 6 |
34242789 | Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC. | 2021 Nov |
1 |
| 7 |
34267282 | Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells. | 2021 Jul 15 |
1 |
| 8 |
32256584 | Pathological Mechanistic Studies of Osimertinib Resistance in Non-Small-Cell Lung Cancer Cells Using an Integrative Metabolomics-Proteomics Analysis. | 2020 |
1 |
| 9 |
30145802 | AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells. | 2019 Jan |
5 |
| 10 |
30623574 | Epithelial growth factor receptor tyrosine kinase inhibitors alleviate house dust mite allergen Der p2-induced IL-6 and IL-8. | 2019 Apr |
1 |
| 11 |
30993382 | Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo. | 2019 Jun |
1 |
| 12 |
31446643 | SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met. | 2019 Nov |
2 |
| 13 |
31555510 | Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines. | 2019 Aug |
1 |
| 14 |
29332537 | AZD9291 Increases Sensitivity to Radiation in PC-9-IR Cells by Delaying DNA Damage Repair after Irradiation and Inducing Apoptosis. | 2018 Mar |
1 |
| 15 |
29797219 | Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype. | 2018 Aug |
1 |